Furthermore, while anti-VEGF drugs in general have mild toxicity profiles and two Phase II trials have shown anti-tumor efficacy (19, 20), a subsequent Phase III trial did not show a significant increase in overall survival (21–23). This evidence concerns the gene VEGFA and neoplasm.